Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

Blood (2023) 142 (Supplement 1): 595.

https://doi.org/10.1182/blood-2023-186998

Published: 2023

Journal Articles

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Blood (2023) 141 (7): 743–755.

https://doi.org/10.1182/blood.2022016975

Published: 2023

Includes: Supplemental data

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-139376

Published: 2020

Journal Articles

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Mirko Kroll, Kirsten Bleckmann, MD, Anja Möricke, MD, Denis Martin Schewe, MD, Martin Stanulla, MD PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Gunnar Cario, MD

Blood (2018) 132 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2018-99-112114

Published: 2018

Journal Articles

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Blood (2018) 132 (3): 264–276.

https://doi.org/10.1182/blood-2017-12-821363

Published: 2018

Includes: Supplemental data

Journal Articles

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Laura Hinze, Stefanie V. Junk, PhD, Norman Klein, Anja Moricke, MD, Gunnar Cario, MD, Christian P. Kratz, MD, Richard S Houlston, MD PhD, Claus R Bartam, MD, Rolf Koehler, PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 3981.

https://doi.org/10.1182/blood.V130.Suppl_1.3981.3981

Published: 2017

Journal Articles

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Stefanie V. Junk, PhD, Norman Klein, Sabine Schreek, Martin Zimmermann, PhD, Anja Möricke, MD, Kirsten Bleckmann, Gunnar Cario, MD, Martin Schrappe, MD PhD, Christian P. Kratz, MD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 884.

https://doi.org/10.1182/blood.V130.Suppl_1.884.884

Published: 2017

Journal Articles

Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study

Benjamin Ole Wolthers, MD, Thomas Leth Frandsen, MD PhD, Andishe Attarbaschi, MD, Shlomit Barzilai, MD, Antonella Colombini, Gabriele Escherich, MD, Marie Grosjean, Ramneek Gupta, PhD, Der-Cherng Liang, MD, Anja Moricke, MD, Chirag J Patel, PhD, Kirsten K Rasmussen, Sujith Samarasinghe, Inge M. Van Der Sluis, MD PhD, Martin Stanulla, MD PhD, Morten Tulstrup, MD, Ester Zapotocka, MD, Kjeld Schmiegelow, MD DMSc

Blood (2017) 130 (Supplement 1): 885.

https://doi.org/10.1182/blood.V130.Suppl_1.885.885

Published: 2017

Journal Articles

Epstein Barr Virus-Associated Lymphoproliferative Disorder during Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia

Sarah Elitzur, MD, Andishe Attarbaschi, MD, Susan Baird, MD, Miri Ben Harosh, MD, Lisa Hjalgrim, PhD, Shai Izraeli, MD, Michaela Kuhlen, MD, Anja Moricke, MD, Shoshana Revel-Vilk, MD, Kjeld Schmiegelow, MD, Martin Schrappe, MD PhD, Melanie Tamesberger, MD, Ajay Vora, MD, Arndt Borkhardt, Prof MD

Blood (2017) 130 (Supplement 1): 1292.

https://doi.org/10.1182/blood.V130.Suppl_1.1292.1292

Published: 2017

Journal Articles

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Blood (2017) 130 (19): 2146–2149.

https://doi.org/10.1182/blood-2017-05-782086

Published: 2017

Includes: Supplemental data

Journal Articles

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Ondrej Hrusak, MD PhD, Valerie De Haas, MD PhD, Ales Luks, Iveta Janotova, Ester Mejstrikova, MD PhD, Kirsten Bleckmann, MD, Anja Moricke, MD, Julie Irving, PhD, Benigna Konatkowska, Thomas B. Alexander, MD MPH, Hiroto Inaba, MD PhD, Kjeld Schmiegelow, MD DMSc, Simone Stokley, FRCPath,, Jorge Gabriel Rossi, PhD, Maria Sara Felice, MD PhD, Luciano Dalla-Pozza, MB BS FRACP, Jessa Morales, Michael Dworzak, MD, Barbara Buldini, MD, Giuseppe Basso, Myriam Campbell, Maria Elena Cabrera, Neda Marinov, Sarah Elitzur, MD, Shai Izraeli, MD, Drorit Luria, PhD, Tamar Feuerstein, PhD, Alexandra Kolenova, MD PhD, Peter Svec, Elena Kreminska, Karen R. Rabin, MD, Sophia Polychronopoulou, MD PhD, Elaine da Costa, Hanne Vibeke Marquart, MD PhD, Antonis Kattamis, MD, Richard Ratei, Dirk Reinhardt, MD PhD, Anthony V Moorman, PhD, Martin Schrappe, MD, Jan Stary, MD D.Sc.

Blood (2016) 128 (22): 584.

https://doi.org/10.1182/blood.V128.22.584.584

Published: 2016

Journal Articles

Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome

Blood (2016) 128 (22): 585.

https://doi.org/10.1182/blood.V128.22.585.585

Published: 2016

Journal Articles

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Stephan Fuhrmann, MD, Leonid Karawajew, Richard Schabath, Anja Moricke, MD, Martin Zimmermann, PhD, Wolf-Dieter Ludwig, Martin Schrappe, MD PhD, Richard Ratei

Blood (2016) 128 (22): 760.

https://doi.org/10.1182/blood.V128.22.760.760

Published: 2016

Journal Articles

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R. Bartram, PhD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, Rita Beier, MD, Gunnar Cario, Franco Locatelli, MD, Giuseppe Basso, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter

Blood (2016) 128 (22): 4.

https://doi.org/10.1182/blood.V128.22.4.4

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Maria Grazia Valsecchi, PhD, Meenakshi Devidas, PhD, Ausiliatrice Lucenti, PhD, Martin Schrappe, MD, Giovanni Cazzaniga, PhD, Anja Moricke, MD, Claus R. Bartram, PhD, Georg Mann, MD, William L. Carroll, MD, Eric Larsen, MD, Naomi Winick, MD, Giuseppe Basso, MD, Valentino Conter, Martin Zimmermann, PhD, Stefan Sushu, Andrea Biondi, MD, Stephen Hunger, MD, Stefania Galimberti, PhD

Blood (2016) 128 (22): 759.

https://doi.org/10.1182/blood.V128.22.759.759

Published: 2016

NARROW

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study

Epstein Barr Virus-Associated Lymphoproliferative Disorder during Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only